van der Heijde et al have published the results of the phase 3 POETYK PsA-1 trial demonstrating that deucravacitinib was superior to placebo in clinical responses, patient-reported outcomes, and structural damage inhibition in patients with psoriatic arthritis (PsA).

The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How great are the benefits and harms? And what didn’t they show me? Feel free to use this in your own journal clubs! This edition: VALOR (brepocitinib in dermatomyositis).

This pooled meta-analyses (n=197,392) shows that exercise reduced pain versus control immediately after the intervention (SMD −0.59; 95% CI −0.65 to −0.53; P0.001). The benefit held across musculoskeletal, inflammatory, neurologic and cancer pain, and for every modality tested.